v3.25.2
Segment Information - Schedule of Segment Revenue and Expenses (Details) - DiamiR Biosciences Corp. [Member] - USD ($)
 12 Months Ended
May 31, 2025
May 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 631,729 $ 1,319,531
Research and development    
Research and development 650,591 1,156,860
Other R&D 2,236
General and administrative    
General and administrative 624,388 614,074
Patents 44,363 30,167
Depreciation 20,828 20,052
Offering costs 150,526
Rent and facilities 53,483 55,600
Other 35,918 86,204
Interest expense 82,046 48,599
Income taxes 17,939 114,403
Net loss (743,235) (614,405)
Salaries and benefits [Member]    
Research and development    
Research and development 449,344 692,875
General and administrative    
General and administrative 105,761 117,883
Consultants and contractors [Member]    
Research and development    
Research and development 176,935 278,837
General and administrative    
General and administrative 213,509 292,234
Stock based compensation [Member]    
Research and development    
Research and development 24,312 182,912
General and administrative    
General and administrative $ 11,934